Patent settlements between originator and generic firms in the pharmaceutical industry have been challenged by … entry and therefore harming consumers. However, it is still heavily disputed under what conditions such patent settlements … contributed to our knowledge about the effects of these patent settlements and the possible rules for their antitrust treatment …

Since the patent system relies on private litigation for challenging weak patents, and patent settlements might … influence the incentives for challenging patents, the question arises whether the antitrust assessment of patent settlements … should also consider their impact on the incentives to challenge potentially invalid patents. Patent settlements in the …

Since the patent system relies on private litigation for challenging weak patents, and patent settlements might … influence the incentives for challenging patents, the question arises whether the antitrust assessment of patent settlements … should also consider their impact on the incentives to challenge potentially invalid patents. Patent settlements in the …

witnessed by the fact that patent applications are very skewed in the covered trade names and patent thickness expands over time … pharmaceutical firms, between patent portfolio and profit margins. …

. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …

the strengthening of the double patenting prohibition: preventing extending exclusive rights beyond the original patent … the inventor in two patents and (2) only applying the prohibition when the earlier patent did not satisfy the technical … meaning of “prior art” within §102 of the Patent Act. The rulings weakening the double patenting doctrine have disregarded …

Patent settlements between originator and generic firms in the pharmaceutical industry are a controversial topic, both … in EU competition policy and U.S. antitrust law. The main concern is that patent settlements, which involve large … challenges. Therefore, certain types of patent settlements might harm consumers, both by defending unjustifiable patents and …

crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in … the US pharmaceutical industry. We estimate the effect of patent length and scope on generic entry prior to the expiration … of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the …

the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent …